Two Onc Docs Thrombotic Thrombocytopenic Purpura (TTP) and other TMAs 2025 UPDATE
11 snips
Aug 26, 2025 Dive into the world of Thrombotic Thrombocytopenic Purpura (TTP) with high-yield facts on its mechanisms, symptoms, and treatment strategies. Explore the urgency of prompt diagnosis and how plasmapheresis can save lives. Learn about Hemolytic Uremic Syndrome (HUS), especially its impact on children and the critical need for early intervention. The discussion covers risk factors and treatment options, making it essential knowledge for both medical professionals and anyone interested in understanding these serious conditions.
AI Snips
Chapters
Transcript
Episode notes
ADAMTS13 Deficiency Drives TTP
- TTP is driven by ADAMTS13 deficiency which prevents cleavage of von Willebrand factor multimers.
- This causes platelet adhesion and aggregation along vessel walls with peripheral destruction of RBCs and platelets.
Treat On Clinical Picture Not Waiting
- Recognize TTP by microangiopathic hemolytic anemia (MAHA) plus thrombocytopenia and schistocytes on the smear.
- Treat presumptively rather than waiting for additional symptoms to prevent high mortality.
Huge Mortality Reduction With Therapy
- Untreated TTP mortality approaches 80–90%, while plasmapheresis historically reduced it to 20–30%.
- Modern treatment has lowered deaths to under 2%, with myocardial infarction as a leading current cause.